0
Deep & Emerging Tech·October 8, 2026·1 min read

I spent 3 days with pharma executives. They're suddenly taking longevity seriously.

Share

Big pharma, FDA officials, and biotech leaders spending days on longevity is a signal that aging is moving from fringe science to pipeline category. For health and data operators, expect more trials, biomarkers, and companion diagnostics focused on prevention and lifespan — and more demand for longitudinal data infrastructure.